Financial reports
10-Q
2023 Q3
Quarterly report
20 Nov 23
NT 10-Q
Notice of late quarterly filing
13 Nov 23
10-Q
2023 Q2
Quarterly report
21 Aug 23
NT 10-Q
Notice of late quarterly filing
14 Aug 23
10-Q
2023 Q1
Quarterly report
22 May 23
10-K/A
2022 FY
Annual report (amended)
19 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-K
2022 FY
Annual report
27 Apr 23
NT 10-K
Notice of late annual filing
29 Mar 23
10-Q
2022 Q3
Quarterly report
21 Nov 22
Current reports
8-K
Regulation FD Disclosure
28 Nov 23
8-K
Regulation FD Disclosure
9 Nov 23
8-K
KAYS’ Oregon Based Psilocybin Treatment Center is on track to be the first of its kind operated by a U.S. Public Company
23 Oct 23
8-K
State-of-the-Art Facility to Offer Access to Psilocybin Treatments
3 Oct 23
8-K
Other Events
15 May 23
8-K
Completion of Acquisition or Disposition of Assets
13 Mar 23
8-K
Other Events
17 Feb 23
8-K
Other Events
30 Jan 23
8-K
Other Events
7 Jul 22
8-K
Departure of Directors or Certain Officers
29 Dec 21
Registration and prospectus
D
$765.00 k in other securities, sold $76.50 k, 2 investors
15 Feb 24
S-8
Registration of securities for employees
15 Sep 22
D
$4M in equity / options / securities to be acquired
4 Sep 20
S-8
Registration of securities for employees
8 Oct 19
S-8
Registration of securities for employees
9 May 18
D
$2.1M in Convertible Debt, sold $2.1M, 1 investor
12 Jan 17
S-8
Registration of securities for employees
4 Nov 16
S-8
Registration of securities for employees
31 Jul 15
S-8 POS
Registration of securities for employees (post-effective amendment)
9 Jan 15
D/A
$1.5M in equity, sold $10K, 1 investor
5 Sep 14
Proxies
No filings
Other
UPLOAD
Letter from SEC
30 Jul 15
UPLOAD
Letter from SEC
15 Jul 15
UPLOAD
Letter from SEC
21 Nov 14
CORRESP
Correspondence with SEC
20 Nov 14
UPLOAD
Letter from SEC
17 Nov 14
UPLOAD
Letter from SEC
12 Feb 14
CORRESP
Correspondence with SEC
10 Feb 14
UPLOAD
Letter from SEC
29 Jan 14
EFFECT
Notice of effectiveness
7 Feb 12
CORRESP
Correspondence with SEC
6 Feb 12